Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ESOMEPRAZOLE Cause Muscle spasticity? 241 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 241 reports of Muscle spasticity have been filed in association with ESOMEPRAZOLE (Esomeprazole Magnesium). This represents 0.3% of all adverse event reports for ESOMEPRAZOLE.

241
Reports of Muscle spasticity with ESOMEPRAZOLE
0.3%
of all ESOMEPRAZOLE reports
1
Deaths
228
Hospitalizations

How Dangerous Is Muscle spasticity From ESOMEPRAZOLE?

Of the 241 reports, 1 (0.4%) resulted in death, 228 (94.6%) required hospitalization, and 204 (84.6%) were considered life-threatening.

Is Muscle spasticity Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ESOMEPRAZOLE. However, 241 reports have been filed with the FAERS database.

What Other Side Effects Does ESOMEPRAZOLE Cause?

Chronic kidney disease (35,281) Acute kidney injury (18,678) Renal failure (14,633) End stage renal disease (10,231) Renal injury (9,440) Gastrooesophageal reflux disease (4,746) Drug ineffective (4,420) Tubulointerstitial nephritis (4,024) Off label use (3,180) Pain (2,898)

What Other Drugs Cause Muscle spasticity?

BACLOFEN (2,893) METHOTREXATE (829) ACETAMINOPHEN (745) TOCILIZUMAB (646) ABATACEPT (628) LEFLUNOMIDE (617) OCRELIZUMAB (610) CERTOLIZUMAB PEGOL (607) GOLIMUMAB (607) ETANERCEPT (606)

Which ESOMEPRAZOLE Alternatives Have Lower Muscle spasticity Risk?

ESOMEPRAZOLE vs ESOMEPRAZOLE\ESOMEPRAZOLE\ESOMEPRAZOLE ESOMEPRAZOLE vs ESOMEPRAZOLE\NAPROXEN ESOMEPRAZOLE vs ESTAZOLAM ESOMEPRAZOLE vs ESTRADIOL ESOMEPRAZOLE vs ESTRADIOL CYPIONATE

Related Pages

ESOMEPRAZOLE Full Profile All Muscle spasticity Reports All Drugs Causing Muscle spasticity ESOMEPRAZOLE Demographics